ValuEngine Upgrades HTG Molecular Diagnostics, Inc

Judith Bessette
Agosto 14, 2017

ValuEngine raised shares of HTG Molecular Diagnostics from a "strong sell" rating to a "sell" rating in a research note on Monday, July 17th.

ValuEngine upgraded shares of HTG Molecular Diagnostics, Inc.

A number of research analysts recently weighed in on the stock. The rating was maintained by H.C. Wainwright on Thursday, June 29 with "Buy". The stock of HTG Molecular Diagnostics Inc (NASDAQ:HTGM) has "Buy" rating given on Friday, July 28 by H.C. Wainwright.

Mossad chief: Iran increasing presence in former ISIS strongholds
The motion, once turns into a law, will grant the same amount to the Quds Forces of Iran's Islamic Revolution Guards Corps (IRGC). Iran said the measures came in response to sanctions imposed by the U.S. in August over Tehran's missile program.

HTG Molecular Diagnostics has an analyst consensus of Moderate Buy, with a price target consensus of $5.75. Rodman & Renshaw raised their target price on HTG Molecular Diagnostics from $4.50 to $6.00 and gave the stock a "buy" rating in a research note on Tuesday, May 16th. The company now has an average rating of "Hold" and a consensus price target of $5.75. Canaccord Genuity lifted their price objective on shares of HTG Molecular Diagnostics from $5.50 to $6.50 and gave the stock a "hold" rating in a research note on Wednesday, April 19th. Comparatively, 5.8% of WaferGen Bio-systems shares are held by company insiders. The stock's market capitalization is $21.43 million. The stock's 50 day moving average is $2.43 and its 200-day moving average is $3.36. The short interest to Htg Molecular Diagnostics Incorporated's float is 17.02%. H.C. Wainwright maintained it with "Buy" rating and $600 target in Wednesday, August 9 report. The medical research company reported ($0.73) earnings per share for the quarter, missing the consensus estimate of ($0.58) by $0.15. HTG Molecular Diagnostics had a negative return on equity of 1,538.49% and a negative net margin of 432.74%. The business had revenue of $1.76 million during the quarter, compared to the consensus estimate of $1.80 million. On average, equities analysts forecast that HTG Molecular Diagnostics will post ($2.25) EPS for the current year. "(NASDAQ:HTGM)" was originally posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this story on another publication, it was copied illegally and republished in violation of USA & global trademark & copyright legislation. The correct version of this piece can be viewed at https://www.chaffeybreeze.com/2017/08/10/fmr-llc-holds-position-in-htg-molecular-diagnostics-inc-nasdaqhtgm-updated.html. Renaissance Technologies LLC increased its stake in HTG Molecular Diagnostics by 32.3% in the fourth quarter. The company's stock had a trading volume of 464,745 shares. UBS Group AG bought a new stake in HTG Molecular Diagnostics during the first quarter worth approximately $137,000. Granahan Investment Management Inc. MA bought a new stake in HTG Molecular Diagnostics during the first quarter worth about $228,000. Vanguard Group Inc. now owns 135,234 shares of the medical research company's stock worth $359,000 after buying an additional 37,841 shares during the period. The Firm focuses on investing in, acquiring and managing a diversified portfolio of residential mortgage assets, other real estate-related securities and financial assets, which the Company refers to as its target assets.

HTG Molecular Diagnostics Inc (NASDAQ:HTGM) has risen 34.13% since August 11, 2016 and is uptrending.

HTG Molecular Diagnostics, Inc.is a commercial-stage firm that develops and markets a technology platform to facilitate the routine use of complex molecular profiling.

Outros relatórios LazerEsportes

Discuta este artigo

SIGA O NOSSO JORNAL